There are currently threeFDA-approved semaglutideproducts: As the world's first and currently onlyweekly glucagon-like peptid-1 receptor agonist (GLP-1RA) formulation forlong-term weight management, Semaglutideweight loss achieves an average weight loss of 17% (16.8kg) and providespatients with multiple health benefits beyond weight loss
What Patients Should Ask Before Starting Treatment Before starting semaglutide, tirzepatide, or any medical weight loss medication, patients should ask whether they are medically appropriate for the medication, which option fits their health history, what side effects to watch for, what dose strategy will be used, what labs should be checked, how blood sugar, liver, kidney, and cardiovascular risk will be monitored, how muscle mass will be protected, what nutrition changes are needed, what happens if they hit a plateau, and whether the medication is coming from a legitimate, licensed pharmacy
This support helps your skin maintain a clearer appearance
It is studied for its lipolytic properties in preclinical research
Increasing patient demand for effective long-term therapies and strong healthcare provider confidence continue to support adoption